HIV Citation List: November 11, 2011 - November 24, 2011

Pubmed citations

1. Computationally-Guided Optimization of a Docking Hit to Yield Catechol Diethers as Potent anti-HIV Agents. Bollini, M., R.A. Domaoal, V.V. Thakur, R. Gallardo-Macias, K.A. Spasov, K.S. Anderson, and W.L. Jorgensen, Journal of Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[22081993].

[PubMed]. HIV_1111-112411.

2. Interactions Between Different Generation HIV-1 Fusion Inhibitors and the Putative Mechanism Underlying the Synergistic anti-HIV-1 Effect Resulting from Their Combination. Cai, L., C. Pan, L. Xu, Y. Shui, K. Liu, and S. Jiang, The FASEB Journal, 2011. [Epub ahead of print]; PMID[22085645].

[PubMed]. HIV_1111-112411.

3. Reactive Aldehyde Metabolites from the anti-HIV Drug Abacavir: Amino Acid Adducts as Possible Factors in Abacavir Toxicity. Charneira, C., A.L. Godinho, M.C. Oliveira, S.A. Pereira, E.C. Monteiro, M.M. Marques, and A.M. Antunes, Chemical Research in Toxicology 2011. [Epub ahead of print]; PMID[22032494].
[PubMed]. HIV_1111-112411.

4. Role of CXCR4 Internalization in the anti-HIV Activity of Stromal Cell-derived Factor-1alpha Probed by a Novel Synthetically and Modularly Modified-chemokine Analog. Dong, C.Z., S. Tian, N. Madani, W.T. Choi, S. Kumar, D. Liu, J.G. Sodroski, Z. Huang, and J. An, Experimental Biology and Medicine, 2011. [Epub ahead of print]; PMID[22101518].
[PubMed]. HIV_1111-112411.

5. Inhibitory Effect of Aqueous Dandelion Extract on HIV-1 Replication and Reverse Transcriptase Activity. Han, H., W. He, W. Wang, and B. Gao, BMC Complementary and Alternative Medicine, 2011. 11(1): p. 112; PMID[22078030].
[PubMed]. HIV_1111-112411.

6. Design, Synthesis and Biological Evaluation of 3-Substituted 2,5-Dimethyl-N-(3-(1H-tetrazol-5-yl)phenyl)pyrroles as Novel Potential HIV-1 gp41 Inhibitors. He, X.Y., P. Zou, J. Qiu, L. Hou, S. Jiang, S. Liu, and L. Xie, Bioorganic & Medicinal Chemistry, 2011. 19(22): p. 6726-34; PMID[22014749].

[PubMed]. HIV_1111-112411.

7. Interplay Between Single Resistance-associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor Sensitivity. Henderson, G.J., S.K. Lee, D.M. Irlbeck, J. Harris, M. Kline, E. Pollom, N. Parkin, and R. Swanstrom, Antimicrobial Agents and Chemotherapy, 2011. [Epub ahead of print]; PMID[22083488].
[PubMed]. HIV_1111-112411.

8. HIV-1 Integrase Inhibitors: A Review of Their Chemical Development. Ingale, K.B. and M.S. Bhatia, Antiviral Chemistry & Chemotherapy, 2011. 22(3): p. 95-105; PMID[22095518].
[PubMed]. HIV_1111-112411.

9. Pre-steady-state Kinetics of Interaction of Wild-type and Multiple Drug-resistant HIV Protease with First and Second Generation Inhibitory Drugs. Kuznetsov, N.A., A.V. Kozyr, M.A. Dronina, I.V. Smirnov, E.N. Kaliberda, A.G. Mikhailova, L.D. Rumsh, O.S. Fedorova, A.G. Gabibov, and A.V. Kolesnikov, Doklady Biochemistry and Biophysics, 2011. 440(1): p. 239-43; PMID[22095129].
[PubMed]. HIV_1111-112411.

10. Antiviral Breadth and Combination Potential of Peptide Triazole HIV-1 Entry Inhibitors. McFadden, K., P. Fletcher, F. Rossi, Kantharaju, M. Umashankara, V. Pirrone, S. Rajagopal, H. Gopi, F.C. Krebs, J. Martin-Garcia, R.J. Shattock, and I. Chaiken, Antimicrobial Agents and Chemotherapy, 2011. [Epub ahead of print]; PMID[22083481].
[PubMed]. HIV_1111-112411.

11. Lead Optimization at C-2 and N-3 Positions of Thiazolidin-4-ones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Murugesan, V., V.S. Tiwari, R. Saxena, R. Tripathi, R. Paranjape, S. Kulkarni, N. Makwana, R. Suryawanshi, and S.B. Katti, Bioorganic & Medicinal Chemistry, 2011. 19(22): p. 6919-26; PMID[21982685].
[PubMed]. HIV_1111-112411.

12. Small Molecular CD4 Mimics as HIV Entry Inhibitors. Narumi, T., H. Arai, K. Yoshimura, S. Harada, W. Nomura, S. Matsushita, and H. Tamamura, Bioorganic & Medicinal Chemistry, 2011. 19(22): p. 6735-42; PMID[22014753].
[PubMed]. HIV_1111-112411.

13. Acetylcholinesterase-inhibiting Alkaloids from Zephyranthes concolor. Reyes-Chilpa, R., S. Berkov, S. Hernandez-Ortega, C.K. Jankowski, S. Arseneau, I. Clotet-Codina, J.A. Este, C. Codina, F. Viladomat, and J. Bastida, Molecules, 2011. 16(11): p. 9520-33; PMID[22086403].
[PubMed]. HIV_1111-112411.

14. In Vitro Activity of Candidate Microbicides Against Cell-associated HIV. Selhorst, P., K. Grupping, T. Bourlet, O. Delezay, K.K. Arien, and G. Vanham, Antimicrobial Agents and Chemotherapy, 2011. [Epub ahead of print]; PMID[22083472].

[PubMed]. HIV_1111-112411.

ISI Web of Knowledge citations

15. Anti-HIV Effect in Vitro of Human Milk Glycoconjugates Glycobiology. Acosta-Blanco, I.O.-F., S Dionisio-Vicuna, M Hernandez-Flores, M Fuentes-Romero, L Newburg, D Soto-Ramirez, LE Ruiz-Palacios, G Viveros-Rogel, M, 2011. 21(11): p. 1475-1476; ISI[000296045300075].
[WOS]. HIV_1111-112411.

16. Synthesis and Oxidation of 2-Hydroxynevirapine, a Metabolite of the HIV Reverse Transcriptase Inhibitor Nevirapine. Antunes, A.N., DA da Silva, JLF Santos, PP Oliveira, MC Beland, FA Marques, MM, Organic & Biomolecular Chemistry, 2011. 9(22): p. 7822-7835; ISI[000296203700033].

[WOS]. HIV_1111-112411.

17. Evaluation of the Immunomodulatory and Antiviral Effects of the Cytokine Combination IFN-alpha and IL-7 in the Lymphocytic Choriomeningitis Virus and Friend Retrovirus Mouse Infection Models. Audige, A.H., U Dittmer, U van den Broek, M Speck, RF, Viral Immunology, 2011. 24(5): p. 375-385; ISI[000296374900004].
[WOS]. HIV_1111-112411.

18. Discovery of a Novel Series of Cyclic urea as Potent CCR5 Antagonists. Duan, M.K., WM Tallant, M Jun, JH Edelstein, M Ferris, R Todd, D Wheelan, P Xiong, ZP, Bioorganic & Medicinal Chemistry Letters, 2011. 21(21): p. 6381-6385; ISI[000296025900034].
[WOS]. HIV_1111-112411.

19. Combined Approach Using Ligand Efficiency, Cross-Docking, and Antitarget Hits for Wild-Type and Drug-Resistant Y181C HIV-1 Reverse Transcriptase. Garcia-Sosa, A.S., S Takkis, K Maran, U, Journal of Chemical Information and Modeling, 2011. 51(10): p. 2595-2611; ISI[000296044200015].

[WOS]. HIV_1111-112411.

20. Exploiting Multivalency: A Designed Dimer of CV-N Shows Improved anti-HIV Activity. Ghirlanda, G., B. Woodrum, M. Ruben, and B. O'Keefe, Glycobiology, 2011. 21(11): p. 1481-1482; ISI[000296045300095].
[WOS]. HIV_1111-112411.

21. Linear and Nonlinear Quantitative Structure-Activity Relationship Modeling of the HIV-1 Reverse Transcriptase Inhibiting Activities of Thiocarbamates. Goodarzi, M., M.P. Freitas, and Y. Vander Heyden, Analytica Chimica Acta, 2011. 705(1-2): p. 166-173; ISI[000295993900020].
[WOS]. HIV_1111-112411.

22. Synthesis and anti-HIV-1 Activity of 4-Substituted-7-(2 '-deoxy-2 '-fluoro-4 '-azido-beta-D-ribofuranosyl) pyrrolo[2,3-d] pyrimidine Analogues. Guo, X.H., Y.J. Li, L. Tao, Q. Wang, S.Y. Wang, W.D. Hu, Z.L. Pan, Q.H. Yang, Y.M. Cui, Z.P. Ge, L.H. Dong, X.J. Yu, H.Y. An, C.J. Song, and J.B. Chang, Bioorganic & Medicinal Chemistry Letters, 2011. 21(22): p. 6770-6772; ISI[000296423700026].
[WOS]. HIV_1111-112411.

23. Triterpene hexahydroxydiphenoyl esters and a Quinic acid purpurogallin carbonyl ester from the Leaves of Castanopsis fissa. Huang, Y.T., T Tanaka, T Matsuo, Y Kouno, I Li, DP Nonaka, G, Phytochemistry, 2011. 72(16): p. 2006-2014; ISI[000295950100009].
[WOS]. HIV_1111-112411.

24. Design, Synthesis, and Biological Activity of a Novel Series of 2,5-Disubstituted furans/pyrroles as HIV-1 Fusion Inhibitors Targeting gp41. Jiang, S.B., S.R. Tala, H. Lu, P. Zou, I. Avan, T.S. Ibrahim, N.E. Abo-Dya, A. Abdelmajeid, A.K. Debnath, and A.R. Katritzky, Bioorganic & Medicinal Chemistry Letters, 2011. 21(22): p. 6895-6898; ISI[000296423700052].
[WOS]. HIV_1111-112411.

25. Modulation of HIV-1 Integrase Activity by Single-stranded Oligonucleotides and Their Conjugates with Eosin Nucleosides. Korolev, S.K., E Anisenko, A Tashlitskii, V Zatsepin, T Gottikh, M Agapkina, J, Nucleotides & Nucleic Acids, 2011. 30(7-9): p. 651-666; ISI[000296072200017].
[WOS]. HIV_1111-112411.

26. Rational Design of 2-Pyrrolinones as Inhibitors of HIV-1 Integrase. Ma, K.W., PH Fu, W Wan, XL Zhou, L Chu, Y Ye, DY, Bioorganic & Medicinal Chemistry Letters, 2011. 21(22): p. 6724-6727; ISI[000296423700017].
[WOS]. HIV_1111-112411.

27. Prospective CCR5 Small Molecule Antagonist Compound Design Using a Combined Mutagenesis/Modeling Approach. Metz, M.B., E Labrecque, J Danthi, SJ Langille, J Harwig, C Yang, W Darkes, MC Lau, G Santucci, Z Bridger, GJ Schols, D Fricker, SP Skerlj, RT, Journal of the American Chemical Society, 2011. 133(41): p. 16477-16485; ISI[000295997500037].
[WOS]. HIV_1111-112411.

28. In Vitro Effect of Anti-Human Immunodeficiency Virus CCR5 Antagonist Maraviroc on Chemotactic Activity of Monocytes, Macrophages and Dendritic Cells. Rossi, R., M. Lichtner, A. De Rosa, I. Sauzullo, F. Mengoni, A.P. Massetti, C.M. Mastroianni, and V. Vullo, Clinical and Experimental Immunology, 2011. 166(2): p. 184-190; ISI[000296422800005].
[WOS]. HIV_1111-112411.

29. Cross-validated Stepwise Regression for Identification of Novel Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Associated Mutations. Van der Borght, K., E. Van Craenenbroeck, P. Lecocq, M. Van Houtte, B. Van Kerckhove, L. Bacheler, G. Verbeke, and H. van Vlijmen, Bmc Bioinformatics, 2011. 12; ISI[000296097400001].
[WOS]. HIV_1111-112411.

30. Neolignans from Schisandra wilsoniana and Their Anti-human Immunodeficiency Virus-1 Activities. Yang, G.Y., R.R. Wang, H.X. Mu, Y.K. Li, W.L. Xiao, L.M. Yang, J.X. Pu, Y.T. Zheng, and H.D. Sun, Chemical & Pharmaceutical Bulletin, 2011. 59(11): p. 1344-1347; ISI[000296300900005].

[WOS]. HIV_1111-112411.

31. Oligonucleotide Conjugates as Inhibitors of HIV-1 Integrase and Reverse Transcriptase. Zatsepin, T., J. Agapkina, S. Korolev, and M. Gottikh, Nucleic Acid Therapeutics, 2011. 21(5): p. A31-A31; ISI[000296231700066].
[WOS]. HIV_1111-112411.

32. A Novel Ribonuclease with Potent HIV-1 Reverse Transcriptase Inhibitory Activity from Cultured Mushroom Schizophyllum commune. Zhao, Y.Z., GQ Ng, TB Wang, HX, Journal of Microbiology, 2011. 49(5): p. 803-808; ISI[000296470200015].
[WOS]. HIV_1111-112411.